JP2022512748A5 - - Google Patents
Info
- Publication number
- JP2022512748A5 JP2022512748A5 JP2021521247A JP2021521247A JP2022512748A5 JP 2022512748 A5 JP2022512748 A5 JP 2022512748A5 JP 2021521247 A JP2021521247 A JP 2021521247A JP 2021521247 A JP2021521247 A JP 2021521247A JP 2022512748 A5 JP2022512748 A5 JP 2022512748A5
- Authority
- JP
- Japan
- Prior art keywords
- colorectal cancer
- pharmaceutical product
- product according
- type
- sided
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748114P | 2018-10-19 | 2018-10-19 | |
| US62/748,114 | 2018-10-19 | ||
| PCT/EP2019/078327 WO2020079209A1 (en) | 2018-10-19 | 2019-10-18 | Abituzumab for the treatment of colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512748A JP2022512748A (ja) | 2022-02-07 |
| JP2022512748A5 true JP2022512748A5 (https=) | 2022-10-25 |
| JP7597450B2 JP7597450B2 (ja) | 2024-12-10 |
Family
ID=68766696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521247A Active JP7597450B2 (ja) | 2018-10-19 | 2019-10-18 | 大腸癌の治療のためのアビツズマブ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12171829B2 (https=) |
| EP (1) | EP3867276A1 (https=) |
| JP (1) | JP7597450B2 (https=) |
| CN (1) | CN113015747A (https=) |
| AU (1) | AU2019362602A1 (https=) |
| CA (1) | CA3116669A1 (https=) |
| IL (1) | IL282313A (https=) |
| TW (1) | TW202027789A (https=) |
| WO (1) | WO2020079209A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
| WO2022261025A1 (en) * | 2021-06-07 | 2022-12-15 | Amgen Inc. | Methods of treating cancer with a combination of sotorasib and trametinib |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2082160C (en) | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| EP0719859B1 (en) | 1994-12-20 | 2003-07-02 | MERCK PATENT GmbH | Anti-alpha V-integrin monoclonal antibody |
| DE10163459A1 (de) | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| RU2390353C2 (ru) | 2004-02-12 | 2010-05-27 | Мерк Патент Гмбх | Высококонцентрированные жидкие композиции анти-egfr антител |
| WO2009010290A2 (en) | 2007-07-17 | 2009-01-22 | Merck Patent Gmbh | Engineered anti-alpha v- integrin hybrid antibodies |
| WO2016041614A1 (en) | 2014-09-17 | 2016-03-24 | Merck Patent Gmbh | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof |
-
2019
- 2019-10-18 JP JP2021521247A patent/JP7597450B2/ja active Active
- 2019-10-18 TW TW108137680A patent/TW202027789A/zh unknown
- 2019-10-18 CN CN201980069047.4A patent/CN113015747A/zh active Pending
- 2019-10-18 CA CA3116669A patent/CA3116669A1/en active Pending
- 2019-10-18 AU AU2019362602A patent/AU2019362602A1/en active Pending
- 2019-10-18 WO PCT/EP2019/078327 patent/WO2020079209A1/en not_active Ceased
- 2019-10-18 EP EP19813413.2A patent/EP3867276A1/en active Pending
- 2019-10-18 US US16/657,828 patent/US12171829B2/en active Active
-
2021
- 2021-04-13 IL IL282313A patent/IL282313A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512748A5 (https=) | ||
| CN108601831B (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| US20070148178A1 (en) | Treatment with anti-vegf antibodies | |
| EP2882454B1 (en) | Combination therapy for the treatment of glioblastoma | |
| CN102006875A (zh) | 吡铂和贝伐单抗治疗结直肠癌的用途 | |
| JP2011511072A5 (https=) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2010515709A5 (https=) | ||
| de Jonge et al. | Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors | |
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2017536408A5 (https=) | ||
| JP2020169208A5 (https=) | ||
| JP2025526003A (ja) | ピペラジン化合物とｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤との組成物、および腫瘍治療におけるその使用 | |
| JP2019038797A5 (https=) | ||
| JP2021530502A5 (https=) | ||
| JP2021518348A5 (https=) | ||
| JP2017515843A5 (https=) | ||
| CA2860889A1 (en) | Tetrahydrofolates in combination with egfr-inhibitors | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| US20150110864A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP2024516970A5 (https=) | ||
| JP2021508699A (ja) | トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用 | |
| JP2018522030A5 (https=) | ||
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы |